Professor Maria Hawkins, UCL - 'Exploring primary resistance of colorectal cancer to chemoradiation'
1:00pm - 2:00pm /
Tuesday 12th May 2026
/ Venue: Physiology seminar room Nuffield Wing
Type: Seminar /
Category: Research
/ Series: Institute of Systems, Molecular and Integrative Biology
- ISMIB Seminar Team
- Admission: Free. Registration not required.
Add this event to my calendar
Click on "Create a calendar file" and your browser will download a .ics file for this event.
Microsoft Outlook: Download the file, double-click it to open it in Outlook, then click on "Save & Close" to save it to your calendar. If that doesn't work go into Outlook, click on the File tab, then on Open & Export, then Open Calendar. Select your .ics file then click on "Save & Close".
Google Calendar: download the file, then go into your calendar. On the left where it says "Other calendars" click on the arrow icon and then click on Import calendar. Click on Browse and select the .ics file, then click on Import.
Apple Calendar: The file may open automatically with an option to save it to your calendar. If not, download the file, then you can either drag it to Calendar or import the file by going to File >Import > Import and choosing the .ics file.
LIVERPOOL CANCER SEMINAR SERIES: SPONSORED BY NORTH WEST CANCER RESEARCH
Professor Maria Hawkins is a clinician scientist in precision radiotherapy committed to improving outcomes through research investigating effects in normal tissue and novel agents-- novel radiation combinations. From 2012 to 2019 she was an MRC Group leader, in Oxford Institute for Radiation Oncology, University of Oxford. She was appointed Professor of Radiotherapy at University College London in 2019 and is currently the clinical director of CRUK City of London Radiation Centre of Excellence, and director of radiotherapy translational research at UCL/UCLH.
Her research investigates the use of AI using multimodal data (imaging, pathology, genomics, radiation dose and clinical features) to develop better patient selection with a focus on gastro-intestinal malignancies, and developing 3D models (precision cut tumour/tissue slices) to study early radiation effect.
She has developed and currently testing in clinical trials, novel radiotherapy including protons in cancers of unmet need (oesophagus pancreas, hepatobilliary) and findings of radiobiology research have been investigated in national studies. Professor Hawkins is the chief investigator of four CRUK funded trials including radiation novel agent combinations in phase I (in oesophageal cancer), and the preoperative proton vs photon radiation surgery and immune treatment study, and for proton therapy as bridge to transplant in cholangiocarcinoma, proton therapy as bridge to CAR-T cell therapy in relapsed glioblastoma trials.
All welcome.
Professor Maria Hawkins is a clinician scientist in precision radiotherapy committed to improving outcomes through research investigating effects in normal tissue and novel agents-- novel radiation combinations. From 2012 to 2019 she was an MRC Group leader, in Oxford Institute for Radiation Oncology, University of Oxford. She was appointed Professor of Radiotherapy at University College London in 2019 and is currently the clinical director of CRUK City of London Radiation Centre of Excellence, and director of radiotherapy translational research at UCL/UCLH.
Her research investigates the use of AI using multimodal data (imaging, pathology, genomics, radiation dose and clinical features) to develop better patient selection with a focus on gastro-intestinal malignancies, and developing 3D models (precision cut tumour/tissue slices) to study early radiation effect.
She has developed and currently testing in clinical trials, novel radiotherapy including protons in cancers of unmet need (oesophagus pancreas, hepatobilliary) and findings of radiobiology research have been investigated in national studies. Professor Hawkins is the chief investigator of four CRUK funded trials including radiation novel agent combinations in phase I (in oesophageal cancer), and the preoperative proton vs photon radiation surgery and immune treatment study, and for proton therapy as bridge to transplant in cholangiocarcinoma, proton therapy as bridge to CAR-T cell therapy in relapsed glioblastoma trials.
All welcome.